Introduction: the risk of venous thromboembolism (VTE) after Spinal injuries was largely realised but the true incidence of which is still variable and unclear. Abstract Patients & method: We retrospectively reviewed the charts of 374 consecutive patients who sustained traumatic spinal injury and admitted acutely to a comprehensive care spinal injuries centre. 159 patients had spinal trauma with spinal cord injury (SCI) and 215 were neurologically intact. The majority of these patients were treated non-surgically and received the same thromboprophylactic regimen started within a median of 2 days post injury. The incidence of clinical VTE (deep Vein thrombosis DVT & Pulmonary Embolism PE) was determined and some risk factors discussed. Results: Among the neurologically intact group one patient developed clinical PE (0.5%). Out of 159 patients with SCI, 23 developed clinically evident VTE (14.5%), 15 had DVT (11.9%), 4 PE (5%) and 4 had both DVT & PE). There was no fatality. Complete SCI lesions were associated with higher incidence of VTE compared to incomplete lesions, 17.6 % & 11% respectively (p
Nabil Alageli, Aheed Osman(7-2021)

Mutations in the TAL1 (T-cell acute leukemia 1) gene were recently described in patients with T-cell acute lymphoblastic leukaemia (T-ALL) and in those with lymphoblastic T-cell non-Hodgkin’s lymphoma (T-NHL). The purpose of this pilot study was to assess the prevalence of mutations in TAL1 gene in T-ALL and TNHL. DNA samples from 15 unrelated healthy controls, 20 T-ALL patients, and 10 T-NHL patients were analyzed using DNA-PCR and direct DNA sequencing to identify sequence genetic variations in TAL1 gene (exons 2 and 3). TAL1 exon 2 mutations were identified in 7.7% adult and 12.5% adolescent T-ALL patients analyzed. TAL1 exon 2 mutations were detected in 16.7% of the adult TNHL patients analyzed. Sequencing of TAL1 exon 3 showed no sequence variation for the T-ALL and T-NHL cancer patients analyzed. No sex difference where observed in the incidences of TAL1 exons 2 mutations between T-ALL and T-NHL patients with and without TAL1 mutations. TAL1 exon 2 missense and frame-shift mutations were present in 44.4% (4/9) and 55.6% (5/9) of T-ALL patients, respectively. However, the frame-shift and missense mutations in the T-NHL patients accounted for, where respectively, 60% (3/5) and 40% (4/5) of all TAL1 exon 2 mutations. Comparing the clinical features showed that there are no differences in PLT and WBC counts as well as the average age between T-ALL and T-NHL patients with and without TAL1 mutations. Overall, these findings indicate that TAL1 mutations are too rare to be of clinical relevance, and do not seem to be significantly associated with the increased T-ALL and T-NHL susceptibility, implying different pathways with respect to TAL1 genetic polymorphisms as a risk factor for T-ALL and T-NHL at least in this population of Libyans.
Amal E. Elarifi, Othman A. El-Ansari, Mohamed A. Al-Griw(12-2016)

Introduction: Smoking is a major avoidable cardiovascular risk factor and is a cause of premature death worldwide. Objectives: To study the prevalence, pattern, and awareness of health hazards of smoking among Libyan diabetic male patients in Tripoli Medical Center, Tripoli, Libya. Patients and Methods: A cross-sectional, clinic-based study using a predesigned questionnaire, the participants were interviewed by the author. The interview covered personal data, and questions about their smoking status, and their awareness of smoking hazards. Results: The overall prevalence of current smoking was 26.4% and past smoking 40.3%. The mean age was 50.8 ± 14.4 years (range 18–75 years). The mean age at which smoking started was 18.6 ± 5.3 years; all current smokers were cigarette smokers. Main reason for quitting smoking was related to health issues while social and religious considerations were the main reasons for never smoking. Conclusions: The prevalence of smoking among Libyan diabetic patients was high; this calls for incorporating smoking cessation services within the diabetes care clinics
Hawa Juma El‑Shareif(12-2019)